4//SEC Filing
Pieper Steven 4
Accession 0001867096-24-000190
CIK 0001867096other
Filed
Nov 25, 7:00 PM ET
Accepted
Nov 26, 5:00 PM ET
Size
9.1 KB
Accession
0001867096-24-000190
Insider Transaction Report
Form 4
Pieper Steven
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-11-22$1.55/sh+19,483$30,199→ 1,441,820 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-22−16,843→ 0 totalExercise: $1.55Exp: 2027-02-04→ Common Stock (16,843 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-22−2,640→ 0 totalExercise: $1.55Exp: 2027-06-12→ Common Stock (2,640 underlying)
Footnotes (2)
- [F1]The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on February 2018, 2019, 2021, and 2021.
- [F2]The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on June 2018, 2019, 2021, and 2021.
Documents
Issuer
Xeris Biopharma Holdings, Inc.
CIK 0001867096
Entity typeother
Related Parties
1- filerCIK 0001875714
Filing Metadata
- Form type
- 4
- Filed
- Nov 25, 7:00 PM ET
- Accepted
- Nov 26, 5:00 PM ET
- Size
- 9.1 KB